// App-Quantinova.ai

: In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis

Researchers

Presenter

  • Anil Aktas-Samur

Principal Investigators

  • Jill Corre

  • Laure Buisson

  • Mariateresa Fulciniti

  • Kenneth C. Anderson

  • Mehmet K. Samur

  • Nikhil C Munshi

  • Herve Avet-Loiseau

Medical Centers

  • Iuct-Oncopole, Toulouse, FRA

  • Unit for Genomics in Myeloma, Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, France

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Toulouse, and CRCT, Toulouse, France, Toulouse, France

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • Early Growth Response 1

  • Tumor protein p53

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved